Clinical Trials Logo

Chemotherapeutic Agent Toxicity clinical trials

View clinical trials related to Chemotherapeutic Agent Toxicity.

Filter by:

NCT ID: NCT00514345 Recruiting - Sarcoma Clinical Trials

CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide

Start date: July 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage. PURPOSE: This clinical trial is looking at the CYP3A5 gene to see if having the gene may be a risk factor for kidney damage in young patients with cancer treated with ifosfamide.

NCT ID: NCT00499798 Completed - Infertility Clinical Trials

Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors

Start date: August 2004
Phase: N/A
Study type: Observational

RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment. PURPOSE: This clinical trial is studying changes in semen or sperm caused by temozolomide in patients with newly diagnosed, progressive, or recurrent primary malignant brain tumors.

NCT ID: NCT00095927 Completed - Clinical trials for Head and Neck Cancer

Randomized Amifostine For SCCHN

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.